136423-13-7

Basic information

• Product Name: 3-PHENETHYL-PIPERIDINE
• Synonyms: 3-PHENETHYL-PIPERIDINE;Piperidine, 3-(2-phenylethyl)-
• CAS NO: 136423-13-7
• Molecular Formula: C₁₃H₁₉N
• Molecular Weight: 189.3
• Mol File: 136423-13-7.mol

Chemical Properties

• Boiling Point: 289.6±9.0 °C(Predicted)
• Appearance: /
• Density: 0.942±0.06 g/cm3(Predicted)
• PKA: 10.38±0.10(Predicted)
• CAS DataBase Reference: 3-PHENETHYL-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PHENETHYL-PIPERIDINE(136423-13-7)
• EPA Substance Registry System: 3-PHENETHYL-PIPERIDINE(136423-13-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 136423-13-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
3-Phenethyl-piperidine is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, 3-Phenethyl-piperidine serves as a versatile building block for the creation of a wide range of organic compounds, contributing to the development of new materials and chemical entities.
Used in Psychoactive Drug Research:
3-Phenethyl-piperidine is used as a subject of research in psychoactive drug development due to its potential psychoactive properties. Its effects on the human body are under investigation to explore its possible use in the treatment of various conditions related to the central nervous system.

InChI:InChI=1S/C13H19N/c1-2-5-12(6-3-1)8-9-13-7-4-10-14-11-13/h1-3,5-6,13-14H,4,7-11H2

Upstream product

• 2633-06-9 (E)-3-(2-phenylvinyl)pyridine 
• 6312-09-0 3-(2-phenylethyl)pyridine 

Downstream Products

• 405065-18-1 (R)-1-(4-Chloro-phenyl)-2-(3-phenethyl-piperidin-1-yl)-ethanone 
• 405089-07-8 [1-(4-Chloro-phenyl)-cyclobutyl]-(3-phenethyl-piperidin-1-yl)-methanone 

Relevant articles and documents

B(C6F5)3-Catalyzed Cascade Reduction of Pyridines

B(C6F5)3 has been found to be an effective catalyst for reduction of pyridines and other electron-deficient N-heteroarenes with hydrosilanes (or hydroboranes) and amines as the reducing reagents. The success of this development hinges upon the realization of a cascade process of dearomative hydrosilylation (or hydroboration) and transfer hydrogenation. The broad functional-group tolerance (e.g. ketone, ester, unactivated olefins, nitro, nitrile, heterocycles, etc.) implies high practical utility.

Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

Lobelane analogues as novel ligands for the vesicular monoamine transporter-2

A series of lobelane analogues has been synthesized and their structure-activity relationships at the vesicular monoamine transporter-2 (VMAT2) have been evaluated. The most potent analogues in this series were the cis-2,6-piperidino analogues, 25b, 27b, 28b, and 30b, with Ki values ranging from 430 to 580 nM.

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

Piperidine derivatives

The invention provides piperidine derivatives of the general formula STR1 or an acid-addition salt or metal salt complex thereof, in which R represents a hydrogen atom or an optionally substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, arylcarbonyl, heterocyclyl or heterocyclyloxy group; R1 represents an optionally substituted alkyl, phenyl, benzyl or cycloalkyl group; R2 represents a hydrogen atom or an optionally substituted alkyl group; one of W and X represents --CH2 --, --CH2 CH2 -- or --O--, the other of W and X being --CH2 -- or --CH2 CH2 or X represents a single chemical bond; m is 0 or 1 and n represents an integer from 0 to 3; processes for their preparation; compositions containing such compounds and their use as fungicides.